Cargando…
Improving Outcomes for Patients With Chronic Lymphocytic Leukemia
Mazyar Shadman, MD, MPH, and Amy Goodrich, CRNP, reviewed data regarding the mechanistic activity, efficacy, and safety of approved and emerging therapeutic options for chronic lymphocytic leukemia (CLL) and strategies for managing adverse events associated with approved therapies for CLL.
Autores principales: | Shadman, Mazyar, Goodrich, Amy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Harborside Press LLC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857328/ https://www.ncbi.nlm.nih.gov/pubmed/33598332 http://dx.doi.org/10.6004/jadpro.2020.11.3.19 |
Ejemplares similares
-
Optimizing Treatment of Chronic Lymphocytic Leukemia
por: Kurtin, Sandra E.
Publicado: (2021) -
COVID-19 Vaccination Response and Its Practical Application in Patients With Chronic Lymphocytic Leukemia
por: Shadman, Mazyar, et al.
Publicado: (2022) -
Contemporary Management of Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
por: Kurtin, Sandra E., et al.
Publicado: (2018) -
Risk-Stratified Treatment in Chronic Lymphocytic Leukemia
por: Stephens, Deborah M., et al.
Publicado: (2016) -
Minimal Residual Disease in Chronic Lymphocytic Leukemia: Highlights From SOHO 2020
Publicado: (2021)